



RNS Number : 5173U  
Roquefort Therapeutics PLC  
24 November 2023

24 November 2023

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Change of Auditor**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that RPG Crouch Chapman LLP has been appointed as its new independent auditor with immediate effect.

The Board has approved the appointment of RPG Crouch Chapman LLP as the Company's auditor for the financial year ending 31 December 2023. The re-appointment of RPG Crouch Chapman LLP for the financial year ending 31 December 2024 will be subject to approval by shareholders at the next Annual General Meeting of the Company to be held in 2024.

In accordance with Section 519 of the Companies Act 2006, the Company's previous auditor, BDO LLP, has confirmed that there are no circumstances connected with their resignation which they considered should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.

**ENDS**

**Enquiries:**

**Roquefort Therapeutics plc**

Stephen West (Chairman) / Ajan Reginald  
(CEO) +44 (0)20 3918  
8633

**Hybridan LLP (Joint Broker)**

Claire Louise Noyce +44 (0)203 764  
2341

**Optiva Securities Limited (Joint Broker)**

Christian Dennis

+44 (0)20 3411  
1881

**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466  
5000

LEI: ?254900P4SISIWOR9RH34

**About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK cell-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on X (formerly Twitter).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPDZMZMVFKGFZM  
Anonymous (not verified)  
Change of Auditor  
33927102  
A  
Fri, 11/24/2023 - 07:00  
LSE RNS  
Executive Changes  
ROQ